AARD

Aardvark Therapeutics Inc

6.22

Aug 24 • 7:37 AM ET -0.60 (-8.80%)

Healthcare Biotechnology USA Micro NASD

Peers: CNTB GALT GNLX IMUX KZIA PYXS VRCA AGEN EDSA SPRO

| Held by: VTI VXF IBB IWC BUSM IBBQ BIB

Index	-
Market Cap	136.12M
Enterprise Value	62.93M
Income	-69.89M
Sales	0.00M
Book/sh	3.42
Cash/sh	3.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	Feb 13, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.82
P/C	1.84
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.63
Current Ratio	12.63
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.21
EPS next Y	-2.56
EPS next Q	-0.72
EPS this Y	-7.54%
EPS next Y	18.64%
EPS next 5Y	5.48%
EPS past 3/5Y	-60.85% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-89.45%
Sales Y/Y TTM	-
EPS Q/Q	0.56%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	24.52% -

Insider Own	41.78%
Insider Trans	0.00%
Inst Own	25.29%
Inst Trans	-6.35%
ROA	-61.06%
ROE	-66.02%
ROIC	-93.09%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.58%
SMA50	4.69%
SMA200	-23.73%
Trades

Shs Outstand	21.88M
Shs Float	12.74M
Short Float	5.12%
Short Ratio	2.55
Short Interest	0.65M
52W High	17.94 -65.33%
52W Low	3.35 85.67%
Volatility	16.95% 12.90%
ATR (14)	0.87
RSI (14)	48.11
Beta	3.80
Rel Volume	0.02
Avg Volume	255.72K
Volume	249

Perf Week	-7.72%
Perf Month	-1.58%
Perf Quarter	37.00%
Perf Half Y	-50.56%
Perf YTD	-52.61%
Perf Year	-36.34%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.36
Target Price	10.12
Prev Close	6.82
Price	6.22
Change %	-8.80%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-26	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$3
Mar-02-26	Downgrade	Stifel	Buy → Hold	$6
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6
Mar-02-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$7
Mar-02-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-28-26	Initiated	B. Riley Securities	Buy	$32
Dec-23-25	Initiated	Oppenheimer	Outperform	$35
Dec-12-25	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy	$47
Nov-07-25	Initiated	BTIG Research	Buy	$26
Sep-29-25	Initiated	Stifel	Buy	$24
Jun-30-25	Initiated	H.C. Wainwright	Buy	$40
Mar-10-25	Initiated	RBC Capital Mkts	Outperform	$21
Mar-10-25	Initiated	Morgan Stanley	Overweight	$29
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight	$50
Mar-10-25	Initiated	BofA Securities	Buy	$22

Show Previous Ratings

Aug-17-26 01:31PM	Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ... (GuruFocus.com)
Aug-11-26 04:53PM	Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.62%
Jul-22-26 04:00PM	Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman (PR Newswire) +6.58%
Jun-25-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
Jun-19-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
09:00AM	Loading…
May-21-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire) +5.13%
May-15-26 07:58AM	FDA hold puts Aardvark Prader-Willi drug in limbo (BioPharma Dive) -32.10%
May-14-26 04:01PM	Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold (GlobeNewswire)
May-07-26 08:00AM	Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-10-26 04:17PM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman (PR Newswire)
Mar-23-26 04:05PM	Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.26%
Mar-04-26 08:54AM	What's Going On With Aardvark Therapeutics Stock On Wednesday? (Benzinga) +15.10%
Mar-02-26 09:49AM	Why Aardvark Therapeutics Just Lost More Than Half Its Value (Investor's Business Daily) -56.20%
07:02AM	Why Is Aardvark Therapeutics Stock Sinking Monday? (Benzinga)
05:23AM	Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran- AMTD Digital, Aardvark, MongoDB In Focus (Benzinga)
03:26AM	Loading…
03:26AM	Safety concerns spur Aardvark to halt key Prader-Willi drug trial (BioPharma Dive)
Feb-27-26 04:05PM	Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome (GlobeNewswire)
Feb-13-26 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-26 08:00AM	Aardvark Therapeutics Announces Leadership Appointments (GlobeNewswire)
08:00AM	Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer (GlobeNewswire)
Feb-10-26 08:00AM	Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome (GlobeNewswire) -6.45%
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +11.66% -7.56%
Dec-10-25 04:05PM	Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome (GlobeNewswire)
Nov-25-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-13-25 04:05PM	Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) -8.66%
Nov-11-25 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.94%
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 12:00PM	Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 (GlobeNewswire) -5.68%
Nov-03-25 05:55PM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:00AM	Loading…
08:00AM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-22-25 08:00AM	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek (GlobeNewswire) -8.28%
Oct-17-25 09:27AM	Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment (Insider Monkey)
Oct-08-25 08:00AM	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome (GlobeNewswire)
Sep-23-25 04:05PM	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire) +6.38%
Sep-22-25 08:01AM	MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug (BioPharma Dive)
Sep-10-25 09:22PM	LB Pharmaceuticals raises $285 million in US IPO (Reuters)
Sep-04-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-27-25 04:10PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) -5.67% -5.56%
Aug-13-25 04:10PM	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) +11.55%
Aug-12-25 08:00AM	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy (GlobeNewswire) -9.96%
Jul-18-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

CEODr. Tien-Li Lee M.D.

CFO & COOMr. Nelson B. Sun M.B.A.

M.P.H.Dr. Manasi Sinha Jaiman M.D.

Chief Scientific OfficerDr. Timothy J. Kieffer Ph.D.

General CounselMr. Christian Zapf J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sun Nelson	Chief Financial Officer	Dec 11 '25	Buy	14.40	3,000	43,200	108,484	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Dec 11 '25	Buy	14.48	7,000	101,395	1,551,613	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Oct 15 '25	Option Exercise	4.24	1,229	5,211	1,544,613	Oct 16 06:14 PM
Jones Bryan	Chief Operating Officer	Oct 15 '25	Option Exercise	4.24	1,250	5,300	1,250	Oct 16 06:12 PM
Lee Tien-Li	Chief Executive Officer	Sep 15 '25	Buy	9.66	10,000	96,624	1,543,384	Sep 16 06:15 AM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 15 '25	Proposed Sale	9.02	10,360	93,413		Sep 15 04:05 PM
Lee Tien-Li	Chief Executive Officer	Sep 10 '25	Buy	7.91	9,000	71,212	1,522,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 11 '25	Buy	7.82	6,000	46,926	1,528,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 12 '25	Buy	8.50	5,000	42,516	1,533,384	Sep 12 08:28 PM
Sun Nelson	Chief Financial Officer	Sep 09 '25	Buy	8.07	6,000	48,440	105,484	Sep 10 05:36 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 02 '25	Proposed Sale	8.51	20,000	170,118		Sep 02 04:05 PM
Lee Tien-Li	Chief Executive Officer	Aug 28 '25	Option Exercise	4.24	17,209	72,966	1,513,384	Aug 29 04:05 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Aug 28 '25	Proposed Sale	8.72	27,691	241,565		Aug 28 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AARD

Aardvark Therapeutics Inc

Upgrade your Finviz experience